Redeye is optimistic about the deal with Biossil worth up to USD60m. This shows there is some value in Medivir's legacy programmes and can provide the company with income in the long term.
ANNONS
Redeye is optimistic about the deal with Biossil worth up to USD60m. This shows there is some value in Medivir's legacy programmes and can provide the company with income in the long term.
